InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas

InveniAI LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, expanded their longstanding relationship with a new, multiple drug discovery agreement. The collaboration will provide Kyowa Kirin with access to InveniAI’s AI Innovation Lab and AI Technology Platform, AlphaMeld, to expand the scope of Kyowa Kirin’s drug discovery programs.

The agreement builds on an ongoing partnership between InveniAI and Kyowa Kirin that began in 2018. The collaboration enables Kyowa Kirin to access InveniAI’s AI technology platform, AlphaMeld, its AI Innovation Lab, and a dedicated team of experts to drive drug discovery efforts across Kyowa Kirin’s therapeutic areas, platforms, and modalities. InveniAI and Kyowa Kirin are now standing at the intersection of state-of-the-art biotechnology and digital technology. Both scientists will work together more interactively to generate innovative drug candidates.

Recommended News : Predictions Series 2022: Interview with Param Kahlon, Chief Product Officer at UiPath

Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin, said, “We are excited about the strategic expansion of our partnership, as it is designed to seamlessly integrate InveniAI’s AI capabilities with our therapeutic platforms to facilitate the discovery of valuable new therapies for patients. Our collaboration, to date, is a testament to the importance of a data-driven approach, and through our partnership with InveniAI, we are embracing the undeniable advantage of technology-aided drug discovery and development.”

“We are pleased to expand our collaboration with Kyowa Kirin, with whom we share a common philosophy of leveraging data and technology to de-risk drug development and deliver better therapies to patients more efficiently. By leveraging our longstanding relationship and combined capabilities – including drug discovery and development infrastructure, and a proven AI platform –we believe we can rapidly achieve this objective,” said Krishnan Nandabalan, Ph.D., President and CEO, InveniAI LLC. “InveniAI is the only AI company with a track record that includes an AI-identified candidate that has undergone successful Phase 3 trials and an NDA submission, in addition to ten other programs at various stages of development. We remain excited about harnessing the potential of this platform for both industry partnerships and our internal drug portfolio.”

Under the terms of the collaboration, InveniAI will receive a committed annual research funding fee for the duration of the collaboration term and obtain rights to receive milestone payments and royalties on sales from Kyowa Kirin.

Recommended AI News: Celsius Integrated Tezos

[To share your insights with us, please write to sghosh@martechseries.com]